Epoch HealthFDA Issues Notice of Nationwide Recall of Common Anxiety Medication

⚖️ Legal / Ethical Complexity

One lot of Xanax XR 3-mg extended-release tablets is under nationwide Class II recall after failing dissolution specifications. Patient calls and pharmacy inquiries will land in your practice before headlines settle.

Professional Impact

• Recall covers single lot of 3-mg extended-release Xanax XR distributed August 2024 through May 2025, NDC 58151-506-91
• FDA classified the action as Class II with negligible risk; no adverse reactions reported despite ongoing recall status
• Failed dissolution specifications mean tablets may not release alprazolam consistently, affecting absorption and steady-state plasma levels
• Alprazolam carries high misuse and dependence risk; abrupt switching or interruption raises withdrawal and rebound anxiety concerns

Action Items

• Review patient charts for the affected lot number and dispensing window
• Document any patient inquiries or clinical observations tied to lot exposure
• Monitor patients on the lot for breakthrough anxiety or unusual symptom patterns
• Establish a transition plan with pharmacy partners for affected prescriptions

More Product Recalls